Adaptimmune Therapeutics Plc Debt/Equity
What is the Debt/Equity of Adaptimmune Therapeutics Plc?
The Debt/Equity of Adaptimmune Therapeutics Plc is 6.15
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on NASDAQ compared to Adaptimmune Therapeutics Plc
What does Adaptimmune Therapeutics Plc do?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Companies with debt/equity similar to Adaptimmune Therapeutics Plc
- Novus Capital has Debt/Equity of 6.15
- Novus Capital has Debt/Equity of 6.15
- Admiral Plc has Debt/Equity of 6.15
- Chorus has Debt/Equity of 6.15
- Chorus has Debt/Equity of 6.15
- Hidili Industry International Development has Debt/Equity of 6.15
- Adaptimmune Therapeutics Plc has Debt/Equity of 6.15
- Balta NV has Debt/Equity of 6.16
- BGC Partners Inc has Debt/Equity of 6.16
- InterGlobe Aviation has Debt/Equity of 6.17
- Kasikornbank Public Co has Debt/Equity of 6.18
- Gen Digital Inc has Debt/Equity of 6.18
- Caisse Régionale de Crédit Agricole Mutuel Nord de France Société coopérative has Debt/Equity of 6.18